1. Prevalence of Autoantibodies to Cyclic Citrullinated Peptide in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: A French Multicenter Study
- Author
-
Joëlle Goetz, Françoise Oksman, Catherine Johanet, Chantal Andre, René-Louis Humbel, Marielle Sanmarco, Jean-Claude Monier, Pascale Chretien, Jean Sibilia, Marie-France Taillefer, Andrée Escande, Alain Chevailler, Nicole Fabien, Nathalie Bardin, Nils-Olivier Olsson, and Françoise Fortenfant
- Subjects
Male ,musculoskeletal diseases ,Allergy ,medicine.medical_specialty ,Arthritis ,Enzyme-Linked Immunosorbent Assay ,Peptides, Cyclic ,Sensitivity and Specificity ,Gastroenterology ,Autoimmune Diseases ,Arthritis, Rheumatoid ,Predictive Value of Tests ,Rheumatoid Factor ,Rheumatic Diseases ,Internal medicine ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,Rheumatoid factor ,skin and connective tissue diseases ,Aged ,Autoantibodies ,business.industry ,Autoantibody ,General Medicine ,Middle Aged ,medicine.disease ,Multicenter study ,Predictive value of tests ,Rheumatoid arthritis ,Immunology ,Cohort ,Female ,France ,business - Abstract
Our objective was to evaluate the prevalence of autoantibodies to cyclic citrullinated peptides (anti-CCP aAbs) in a cohort of patients with a variety of inflammatory or non-inflammatory rheumatic diseases other than rheumatoid arthritis (RA). Six hundred and nine serum samples were tested for anti-CCP aAbs and for rheumatoid factor (RF) using enzyme-linked immunosorbent assays and immunonephelometry. The prevalence of anti-CCP aAbs and RF reached 10% and 25%, respectively, using the positive cutoff value suggested by the manufacturers. Using a higher cutoff value (50 U/ml) for both aAbs, the prevalence was lower with 6% and 16%, respectively. The specificity of both markers for RA thus reached 94% and 84%, respectively. Anti-CCP aAbs were found to be elevated in inflammatory and also in non-inflammatory rheumatic diseases in the same proportion. Clinical data obtained for 36 positive patients showed that 17% developed RA within 5 years. In conclusion, anti-CCP aAbs are clearly more specific than RF for RA. Follow-up of anti-CCP aAbs-positive patients with inflammatory or non-inflammatory rheumatic diseases other than RA could be important considering the predictive value of these aAbs for the development of RA.
- Published
- 2008